BRISBANE, Calif., Oct. 28, 2008 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, today announced that its lead drug candidate, BSI-201, which is in Phase 2 clinical trials for multiple cancer indications, has been selected as one of the Top 10 Most Interesting Oncology Projects Available for Partnering. An independent committee assembled by Windhover Information made the selection. Windhover is a leading provider of business information products and services to senior executives in the pharmaceutical, biotechnology and medical device industries.
